All In Biotech

Drug Trial Radar · NCT04530123

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on a Gluten-Free Diet

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Jun 23, 2022

Primary completion

Dec 9, 2025

Study completion Jan 8, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Aug 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease (CeD) on a gluten-free diet (GFD). Participants will receive TAK-101 and/or placebo through the vein on Day 1 and Day 8. All participants will receive active treatment at Week 24.

Conditions

  • Celiac Disease

Interventions

  • PlaceboDrug

    TAK-101 matching placebo intravenous infusion

  • TAK-101Drug

    TAK 101 intravenous infusion

  • GlutenDietary supplement

    Powder form (vital wheat gluten)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs) in Human Leukocyte Antigens Density Quotient (HLA-DQ2.5-positive) Participants Based on Results of a Gliadin-Specific Enzyme-Linked Immunospot (ELISpot) AssayTime frame: Baseline (Day 15), Week 3 (Day 20)

Locations

48 sites in 4 countries. Site status is shown where the registry gives one.

  • One of a Kind Clinical Research Center LLC

    Scottsdale, Arizona

  • Gastroenterology and Liver Institute

    Escondido, California

  • Cadena Care Institute, Inc.

    Poway, California

  • Asthma and Allergy Associates, PC

    Colorado Springs, Colorado

  • GCP Clinical Research, LLC

    Tampa, Florida

  • Agile Clinical Research Trials

    Atlanta, Georgia

  • Lemah Creek Clinical Research

    Burr Ridge, Illinois

  • Gastroenterology Associates, PA

    Rockford, Illinois

  • Rockford Gastroenterology Associates, Ltd.

    Rockford, Illinois

  • Berkshire Medical Center

    New Albany, Indiana

  • Gastroenterology Health Partners, PLLC

    New Albany, Indiana

  • Boston Specialists

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Berkshire Medical Center, Inc.

    Pittsfield, Massachusetts

  • Clinical Research Institute of Michigan, LLC

    Chesterfield, Michigan

  • Wellness Clinical Research

    Chesterfield, Michigan

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico

  • Basil Clinical

    Inwood, New York

  • Mount Sinai

    New York, New York

  • Columbia University Medical Center. New York Presbyterian Hospital

    New York, New York

  • East Carolina Gastroenterology, PA

    Jacksonville, North Carolina

  • GI Alliance-Rhode Island

    Providence, Rhode Island

  • Amel Med LLC

    Georgetown, Texas

  • Care Access Research - Salt Lake City

    Ogden, Utah

  • St Vincent's Hospital Melbourne

    Fitzroy, Australia

  • Mater Hospital Brisbane

    South Brisbane, Australia

  • Royal Melbourne Hospital

    Parkville, AU, Australia

  • Emeritus Research, Sydney

    Botany, NS, Australia

  • Coral Sea Clinical Research Institute

    North Mackay, Queensland, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Emeritus Research, Melbourne

    Camberwell, Victoria, Australia

  • The Northern Hospital

    Epping, Victoria, Australia

  • St John of God Midland

    Midland, Western Australia, Australia

  • Gastroenterology and Internal Medicine Research Institute (GIRI)

    Edmonton, Alberta, Canada

  • PerCuro Clinical Research Ltd.

    Victoria, British Columbia, Canada

  • McMaster University

    Hamilton, Ontario, Canada

  • Scott Shulman Medicine Professional Corporation

    North Bay, Ontario, Canada

  • DIEX Recherche Quebec Inc.

    Québec, Quebec, Canada

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.